Attapulgite, Pectin & Magnesium Trisilicate

Verify with FDA CVM →

25 adverse event reports submitted to the FDA

Important: Adverse event reports do not establish that a drug caused or contributed to the event. Consult your veterinarian before making treatment decisions.
25
Total Reports
5
Deaths Reported
2000.0%
Death Rate

Active Ingredients

Attapulgite, Pectin & Magnesium Trisilicate

Administration Routes

OralUnknownTopical

Species Affected

Dog 22
Cat 3

Most Affected Breeds

Retriever - Labrador 4
Domestic Shorthair 3
Terrier - Yorkshire 2
Terrier - Irish Soft-coated Wheaten 2
Shepherd Dog - German 2
Shepherd Dog - Australian 1
Crossbred Canine/dog 1
Doberman Pinscher 1
Schnauzer (unspecified) 1
Boxer (German Boxer) 1

Most Reported Reactions

Diarrhoea 13
Vomiting 13
Other abnormal test result NOS 9
Anorexia 7
Lethargy (see also Central nervous system depression in 'Neurological') 5
Elevated creatinine 5
Elevated blood urea nitrogen (BUN) 5
Abnormal radiograph finding 4
Weight loss 4
Death by euthanasia 4
Elevated alanine aminotransferase (ALT) 3
Elevated serum alkaline phosphatase (SAP) 3

Outcome Breakdown

Ongoing
13 (52.0%)
Recovered/Normal
6 (24.0%)
Euthanized
4 (16.0%)
Outcome Unknown
1 (4.0%)
Died
1 (4.0%)

Data Summary

Metric Value
Total adverse event reports 25
Reports involving death 5
Case-fatality rate (reported events) 2000.0%
Distinct species in reports 2
Distinct breeds in reports 17
Distinct reactions reported 20
Active ingredients on file 1

Source: FDA Center for Veterinary Medicine — Adverse Event Reporting (CVM AER). Counts reflect voluntary reports only.

Attapulgite, Pectin & Magnesium Trisilicate Adverse Event Insights

The FDA Center for Veterinary Medicine database currently holds 25 adverse event reports referencing Attapulgite, Pectin & Magnesium Trisilicate, including 5 reports in which the animal died — a 2000.0% case-fatality figure among reported events only, not a population-level mortality rate. Active ingredient on file: Attapulgite, Pectin & Magnesium Trisilicate. Reported administration routes include Oral, Unknown, Topical. These numbers reflect voluntary submissions from pet owners, veterinarians, and manufacturers and therefore under-represent mild events and over-represent severe ones — a pattern the FDA has documented repeatedly for pharmacovigilance datasets.

The species most frequently named in Attapulgite, Pectin & Magnesium Trisilicate reports are Dog (22 reports), Cat (3 reports), with Dog accounting for the largest share. Within those species, Retriever - Labrador (4), Domestic Shorthair (3), Terrier - Yorkshire (2) appear most often — though breed popularity and ownership density shape these counts as much as any drug-specific sensitivity. This distribution matters because the same active ingredient can behave very differently across body sizes, ages, and species physiology.

The most commonly reported clinical signs associated with Attapulgite, Pectin & Magnesium Trisilicate are Diarrhoea (13), Vomiting (13), Other abnormal test result NOS (9), Anorexia (7). Of the 25 reports with a coded outcome, Ongoing is the leading category at 52.0%. Because FDA adverse event data describes correlation rather than causation, these figures are best used to frame informed questions with a veterinarian and to compare reporting patterns across related products — not as a standalone safety verdict on Attapulgite, Pectin & Magnesium Trisilicate.

Source: FDA Center for Veterinary Medicine — Adverse Event Reports FDA Center for Veterinary Medicine — Adverse Event Reports Data reflects voluntary submissions and may not represent actual incidence rates

Related

Data sourced from official AKC, AVMA, ACVO, and breed-club veterinary references. See our methodology for details. Retrieved and formatted by PlainBreed Editorial